Skip to main content
Grifols S.A. logo

Grifols S.A. — Investor Relations & Filings

Ticker · GRF ISIN · ES0171996087 LEI · 959800HSSNXWRKBK4N60 MC Manufacturing
Open in API
Filings indexed 684 across all filing types
Latest filing 2024-04-04 Regulatory Filings
Country ES Spain
Listing MC GRF

About Grifols S.A.

https://www.grifols.com/en/home

Grifols S.A. is a global healthcare company specializing in the development, production, and marketing of plasma-derived medicines and other biopharmaceutical solutions. As a leading producer of therapies derived from human plasma, the company addresses the needs of patients with chronic, rare, and life-threatening conditions. Its core activities encompass the entire plasma value chain, from collection to the manufacturing of essential protein therapies. In addition to its primary Biopharma division, Grifols provides a comprehensive portfolio of diagnostic solutions for transfusion medicine and clinical laboratories, as well as bio supplies for pharmaceutical and research applications. The company is committed to advancing patient health and well-being through scientific innovation and high standards of quality and safety.

Recent filings

Filing Released Lang Actions
FORM 6-K
Regulatory Filings
2024-04-04 English
FORM 6-K
Regulatory Filings
2024-04-02 English
D. José Ignacio (Nacho) Abia ha pasado a tener la categoría de "consejero ejecutivo".
Board/Management Information Classification · 98% confidence The document is a formal communication from Grifols, S.A. announcing a change in the status of a board member, D. José Ignacio (Nacho) Abia, from 'other external' to 'executive director' (Consejero Delegado) effective April 1st. This change is explicitly related to the composition and roles within the company's board of directors and senior management. This directly aligns with the definition of Board/Management Information (MANG). The document is short and appears to be a regulatory disclosure of this specific event.
2024-04-02 Spanish
FORM 6-K
Regulatory Filings
2024-03-22 English
La Sociedad remite el escrito de conclusiones alcanzadas por la CNMV en relación con el informe Gotham.
Legal Proceedings Report Classification · 99% confidence The document is an official communication from Grifols, S.A. to the CNMV (Comisión Nacional del Mercado de Valores - the Spanish securities market regulator). The title is "INFORMACIÓN PRIVILEGIADA" (Inside Information) and it explicitly states that the company is communicating the 'conclusiones alcanzadas por la CNMV en relación con el informe Gotham' (conclusions reached by the CNMV regarding the Gotham report), which is attached as an Annex. The content details the findings and conclusions of the CNMV's investigation into Grifols' financial reporting following the critical report by Gotham City Research. This is not a standard periodic report (like 10-K or IR), nor is it a simple announcement of a report's publication (RPA). Instead, it is a formal disclosure of regulatory findings and conclusions regarding past financial statements and governance, which falls under the scope of regulatory disclosure or specific legal/investigative updates. Given the nature of disclosing findings from a regulatory investigation concerning financial statements and governance issues, it is most closely aligned with a specific regulatory disclosure. Since it is a formal communication of regulatory findings rather than a standard financial filing form (like 10-K, IR, or ER), and it is being released as 'Información Privilegiada' (Inside Information) to the regulator, the most appropriate general category for significant, non-standard regulatory disclosures that don't fit elsewhere is 'Regulatory Filings' (RNS). However, the content is highly specific: it is the company communicating the *conclusions* of the regulator (CNMV) regarding an investigation into financial reporting quality, which is a critical piece of information for investors. If we look at the definitions, it is not an Audit Report (AR), nor a Governance Report (CGR), but a direct response/disclosure related to regulatory scrutiny. Given the context of Spanish market regulation (CNMV) and the nature of the content (conclusions of an investigation into financial reporting quality), it functions as a significant regulatory disclosure. 'RNS' (Regulatory Filings) is the best fit as a catch-all for significant, non-standard regulatory communications.
2024-03-21 Spanish
Motivo de la notificación: Persona con Responsabilidad de Dirección
Director's Dealing Classification · 100% confidence The document is titled "STANDARD FORM FOR NOTIFICATION AND PUBLIC DISCLOSURE OF TRANSACTIONS BY PERSONS DISCHARGING MANAGERIAL RESPONSIBILITIES AND PERSONS CLOSELY ASSOCIATED WITH THEM". This form is used to report personal share transactions by company directors and executives (insider trades). This directly corresponds to the definition for Director's Dealing (DIRS). The content details a transaction by 'Raimon Grifols Roura', identified as an 'Consejero Ejecutivo' (Executive Director), involving the acquisition of shares (RSUs).
2024-03-19 Spanish

Browse filings by year

23 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.